Lyell Immunopharma (LYEL) Retained Earnings (2020 - 2026)

Lyell Immunopharma has reported Retained Earnings for 7 years, with the latest figure at -$9000.0 in Q1 2026.

• Quarterly Retained Earnings rose 100.0% year-over-year to -$9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9000.0 (up 100.0% YoY) and the FY2025 annual result came in at $242000.0, up 100.02% from the prior year.
• Retained Earnings retreated to -$9000.0 in Q1 2026 per LYEL's latest filing, from $242000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $1.8 billion in Q3 2025 and troughed at -$1.4 billion in Q1 2025.
• A 5-year average of $9.4 million and a median of -$1.2 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings tumbled 1430863.83% in 2024, then surged 438097.48% in 2025.
• Over 5 years, Retained Earnings stood at -$767.5 million in 2022, then soared by 99.99% to -$94000.0 in 2023, then sank by 1430863.83% to -$1.3 billion in 2024, then jumped by 100.02% to $242000.0 in 2025, then sank by 103.72% to -$9000.0 in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$9000.0, $242000.0, and $1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.